Loading...
Co-Diagnostics reported a strong second quarter with revenue of $27.4 million, pre-tax income of $11.9 million, and diluted EPS of $0.33. The company is focused on delivering high-quality diagnostic testing kits and is positioned for future growth with investments in talent and R&D.
Delivered strong quarterly results following record results in 2020.
Cultivated distributor relationships throughout the United States and abroad, resulting in record sales.
Focused on delivering high-quality diagnostic testing kits to customers worldwide amidst emerging COVID-19 variants.
Investments in talent and R&D continue to yield positive results, particularly with the Eikon point of care technology platform.